Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Pathogenic yeasts and fungi: A growing health concern

14.05.2003


When a few weeds appear on your front lawn, you can easily pick them off one by one. But if they start taking over the yard, the picking becomes laborious, and you may need to turn to a chemical weed-killer to hold the invaders in check. After several applications of the herbicide, however, the weeds could become resistant, forcing you to use an even more powerful solution. Meanwhile, the survival of your lawn hangs in the balance.

Like weeds in a lawn, pathogenic fungi and yeasts (single-celled fungi) can invade and overtake our bodies. In people with healthy immune systems, cells called macrophages and neutrophils engulf these pathogens, nipping them in the bud. But when the immune system is weakened by disease or drugs, fungi – much like weeds in your garden – can grow unchecked.

For example, when the neutrophil cell count is low, an invasion of the common yeast Candida albicans can cause a systemic infection. The result can be an overgrowth of the yeast in various organs – and possibly death. In such cases, physicians often turn to anti-fungal drugs to keep the yeast under control. But over time, yeasts and fungi can develop resistance to the treatments, forcing medical researchers to devise more potent drugs. Meanwhile, the patient’s health hangs in the balance.



From Harmless to Harmful

For millennia, yeasts and fungi have enjoyed relatively good relations with humans. Despite their abundance – they appear on plant leaves and flowers, soil, salt water, baked goods and beer, as well as in our gastrointestinal tracts and skin surfaces – very few yeasts and fungi trigger disease in healthy people. Present in about half of us, the most common fungal pathogen, Candida albicans, can cause easily treatable ailments such as vaginitis, diaper rash and oral thrush. But according to recent reports, yeasts and fungi are impacting some people much more severely: An increasing number of hospital patients with compromised immune systems are succumbing to fungal pathogens, leading to thousands of deaths each year.

"Fungal pathogens are becoming much more prevalent in systemic infections because we have a larger immunocompromised patient population," says Robert T. Wheeler, a postdoctoral fellow in the lab of Gerald Fink, a Member and former director at Whitehead Institute for Biomedical Research. This includes cancer, AIDS and organ transplant patients. If these patients are infected by the Candida species – the fourth most common bloodstream infection in hospitals – they face a nearly 40 percent mortality rate. Treatment is limited to a small number of marginally effective anti-fungal drugs that produce significant side effects and to which the pathogens are becoming increasingly resistant. "Antibiotics can kill bacteria without bad side effects, but because fungi contain cellular machinery and proteins similar to our own, it’s hard to find agents to kill fungi that don’t have negative effects on us," Wheeler explains.

Probing the Immune System Response

Containing the "weeds" within us requires novel approaches. Researchers in Fink’s lab are investigating more virulent forms of fungi to improve our understanding of how fungal pathogens interact with the immune system, and to develop more effective anti-fungal agents.

"People used to study pathogens by taking a microorganism and debilitating it by making a mutation," observes Fink, who also is a professor of genetics at Massachusetts Institute of Technology. "But these debilitated organisms weren’t very informative about the healthy pathogen. A much more fruitful approach is if you make something that’s hypervirulent, because genes that lead to a souped-up microbe tell you a great deal about how pathogens behave."

A case in point is an experiment that Wheeler, Fink and collaborators at Boston University and Israel’s Tel Aviv University published earlier this year on Saccharomyces cerevisiae (baker’s yeast). Used in bread baking, beer brewing and wine fermentation, Saccharomyces has appeared more often in immunocompromised patients, raising several questions about its origin, survival and virulence in humans.

In their study, which appeared in the Feb. 14 Proceedings of the National Academy of Sciences, the scientists compared the virulence in laboratory mice of Saccharomyces strains isolated from the human bloodstream, a rotting fig and a carefully cultivated, fully sequenced strain of baker’s yeast strains. These comparisons were made before and after knocking out a gene called SSD1, which contributes to the yeast cells’ surface characteristics and to their ability to grow at higher temperatures.

In mice, without gene modification, the lab strain and human isolate were not virulent while the fig isolate was virulent. But when the scientists knocked out the SSD1 gene, they found that the virulence of the plant and clinical strains rose substantially. Wheeler and his colleagues determined that the removal of SSD1 changed the composition and cell wall architecture of the yeast cell surface. The mutant yeast also evoked a more powerful response from immune cells. As a result, the researchers suggest, the immune system’s macrophage cells may have misrecognized the yeasts and overreacted, provoking an imbalance in the immune system – a systematic inflammatory response that ultimately caused the mice to die of septic shock.

What’s significant about this study is that it probes the minimum requirement for fungi to cause disease, says Phillips Robbins, professor of molecular and cell biology at Boston University’s School of Dental Medicine. "Defining the subtle mutations that lead to this pathogenic lifestyle will provide important new insights into the primary or underlying mechanisms used by other more aggressive fungi to produce disease," Robbins maintains.

Wheeler expects this study to accelerate efforts to understand how the immune system detects pathogenic yeast. "We aim to understand which molecular patterns of the yeast are recognized by the immune system, and how it responds," he says. "The more you understand how the innate immune system works, the more you can enable people to respond better to pathogens, and learn how to regulate the immune system when it gets out of control."

Research Thrusts at the Fink Lab and Beyond

Researchers at Whitehead take a broad-based approach to the study of pathogenic yeasts and fungi, combining new genomic approaches and genetic techniques to boost scientists’ knowledge of how fungal pathogens infect human, animal and plant hosts. "We’re trying to understand the basic mechanisms of growth, development, pathogenesis and virulence of these organisms," says Wheeler, "in a way that we hope sheds light not only on virulence and pathology, but also leads to a greater understanding of how life works."

One key area of this research focuses on the mechanisms that enable yeasts such as Candida albicans to switch between two different forms. For example, when Candida enters the respiratory tract, the spore-like yeasts germinate and become an elongated, filamentous row of cells. Like other yeasts, they multiply through cell division, or grow as filaments. It is this filamentation that enables Candida’s cell walls to bind to the respiratory tract. "This ability to exist in two different forms give fungi a real advantage and flexibility to deal with immune systems," says Wheeler.

Ongoing investigations in Fink’s lab of how Candida albicans interacts with immune system cells are enabling labs elsewhere to explore this yeast at the molecular level. Fink’s team and other researchers in the field want to determine how the immune system recognizes and defends against different fungal pathogens and explore the mechanisms that enable these pathogens to resist anti-fungal drugs. A better understanding of these processes could help researchers develop more accurate and effective drugs to contain them.

As it generates new knowledge, this research also may spin off new technologies. Work by Wheeler and Fink on Saccharomyces could lead to a number of beneficial clinical applications. For example, Wheeler notes that a drug combining Saccharomyces and a bacterium found in yogurt called lactobacillus could be used as a probiotic that restores a healthy balance of intestinal microbes. The drug would thereby decrease the severity and duration of diarrhea associated with antibiotic use. In addition, he says, Saccharomyces may be employed as a vaccine delivery vector.

Two other potential applications are in the pipeline. Two years ago, Whitehead postdoctoral fellow Mike Lorenz identified a metabolic pathway that’s fungal-specific and required for infection. The Institute has applied for a patent to help develop novel antifungal drugs that target specific fungi. Meanwhile, another postdoctoral fellow, Todd Reynolds, has developed Saccharomyces as a model for understanding the formation of biofilms, or communities of microorganisms that attach to a solid surface. Groups of yeast cells that tend to be more resistant to anti-fungal drugs, fungal biofilms, are potentially a major cause of untreatable fungal infections.

And these ideas only skim the surface. As researchers learn more about pathogenic fungi and yeast, more questions are bound to arise, the answers to which could offer a larger arsenal against the disease-causing agents.


By Mark Dwortzan

The research was supported by the National Institutes of Health. Robert T. Wheeler is a Burroughs Wellcome Fellow of the Life Science Research Foundation.

Kelli Whitlock | EurekAlert!
Further information:
http://www.wi.mit.edu/home.html

More articles from Health and Medicine:

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

nachricht Direct conversion of non-neuronal cells into nerve cells
03.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Microscopic trampoline may help create networks of quantum computers

17.07.2018 | Information Technology

In borophene, boundaries are no barrier

17.07.2018 | Materials Sciences

The role of Sodium for the Enhancement of Solar Cells

17.07.2018 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>